ExpreS2ion Biotech Holding AB (publ)

Stockholm Stock Exchange EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 8.31

ExpreS2ion Biotech Holding AB (publ) Price to Sales Ratio (P/S) is 8.31 on January 14, 2025, a 675.67% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

ExpreS2ion Biotech Holding AB (publ) 52-week high Price to Sales Ratio (P/S) is 10.26 on December 11, 2024, which is 23.49% above the current Price to Sales Ratio (P/S).
ExpreS2ion Biotech Holding AB (publ) 52-week low Price to Sales Ratio (P/S) is 0.24 on July 29, 2024, which is -97.11% below the current Price to Sales Ratio (P/S).
ExpreS2ion Biotech Holding AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 1.86.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ)

CEO	Mr. Bent U. Frandsen MSc
IPO Date	July 29, 2016
Location	Denmark
Headquarters	SCION-DTU Science Park
Employees	18
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.

Key trends

Past 5 years